December 14, 2020 06:55 AM ESTUpdated 12:03 PM

Covid-19 roundup: Trump walks back plans to prioritize White House staff for vaccine; AstraZeneca drops subgroup of children from vaccine trial — report

Amber Tong

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

As Americans wait to receive the first doses of Pfizer and BioNTech’s recently authorized Covid-19 vaccine, President Donald Trump is walking back plans for White …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Trump walks back plans to prioritize White House staff for vaccine; AstraZeneca drops subgroup of children from vaccine trial — report

Amber Tong

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Covid-19 roundup: Trump walks back plans to pri­or­i­tize White House staff for vac­cine; As­traZeneca drops sub­group of chil­dren from vac­cine tri­al — re­port

Senior Editor

Editor

Sign up to read this article for free.

more like this

Covid-19 roundup: Trump walks back plans to prioritize White House staff for vaccine; AstraZeneca drops subgroup of children from vaccine trial — report